EGAPP Finds No Benefit to Marketed Genetic Tests for Cardiovascular Disease Risk

The "magnitude of net health benefit" from use of eight marketed tests analyzing 58 variants and 29 genes reviewed by the Evaluation of Genomic Applications in Practice and Prevention Working Group is "negligible," the expert panel wrote in a statement.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories